Analyst Research

Report Title Price
Provider: Griffin Securities, Inc.
$12.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ligand Pharmaceuticals Inc reaffirms FY 2014 guidance; gives Q2 2014 guidance below analysts' estimates


Wednesday, 7 May 2014 08:30am EDT 

Ligand Pharmaceuticals Inc:Affirming FY 2014 total revenues to be between $62 and $64 million.FY 2014 non-GAAP earnings per diluted share to be between $1.40 and $1.45.FY 2014 revenue of $63 million and EPS of $1.46 - Thomson Reuters I/B/E/S.Expects Q2 2014 total revenues to be between $9.0 to $9.5 million.Q2 2014 non-GAAP earnings per diluted share to be between $0.11 and $0.13.Q2 2014 non-GAAP earnings per diluted share guidance does not include the effects of any increase or decrease in contingent liabilities and non-cash stock-based compensation expense.Q2 2014 revenue of $13 million and EPS of $0.23 - Thomson Reuters I/B/E/S. 

Company Quote

55.19
0.82 +1.51%
12:43pm EDT